Creative Medical Technology Holdings, Inc. (CELZ) Cash Flow Statement
Where CELZ’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$5.9M
- Capital expenditures
- $5 0.1% of revenue
- Free cash flow
- −$5.9M −97,607.4% margin
- Returned to shareholders
- $10,000
- Change in cash
- $1.3M cash at year-end $7.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
CELZ operating cash flow, capex and free cash flow
CELZ cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$445,2322016 | −$5.9M2025 | — | |
| Capital expenditures | $10,0002016 | $52025 | −57.0%/yr | |
| Free cash flow | −$455,2322016 | −$5.9M2025 | — | |
| Free cash flow margin | −18,533.8%2017 | −97,607.4%2025 | −79,073.6 pts | |
| Stock-based compensation | $2,5652016 | $3,4852025 | +3.5%/yr | |
| Share buybacks (net) | $02016 | $10,0002025 | — | |
| Capex / revenue | 0.0%2017 | 0.1%2025 | +0.1 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CELZ cash flow by activity
CELZ net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CELZ cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$6.0M | −$5.5M | −$5.3M | −$10.1M | $19.2M | −$36.3M | −$8.5M | −$13.7M | −$2.7M | −$766,072 |
| Depreciation & amortization | $123,327 | $110,452 | $94,584 | $92,084 | $92,084 | $66,792 | $26,950 | $21,144 | $15,995 | $9,356 |
| Stock-based compensation | $3,485 | $36,648 | $36,648 | $68,746 | $595,380 | $170,323 | $0 | $1,877 | $144,160 | $2,565 |
| Change in working capital | $13,335 | $45,089 | −$2.8M | $2.2M | $249,465 | $692,794 | $62,202 | $129,426 | $158,062 | $308,919 |
| Other non-cash items | −$1,584 | $0 | −$34,087 | $0 | −$22.4M | $35.0M | $7.2M | $12.5M | $1.5M | $0 |
| Cash from operating activities | −$5.9M | −$5.3M | −$8.0M | −$7.8M | −$2.2M | −$434,556 | −$1.2M | −$1.1M | −$889,621 | −$445,232 |
| Investing activities | ||||||||||
| Capital expenditures | −$5 | −$200,000 | −$100,000 | −$4 | $0 | −$250,000 | −$3 | $0 | $0 | −$10,000 |
| Investments (net) | $0 | $6.3M | −$2.7M | −$10.1M | −$450,000 | −$250,000 | — | — | $0 | −$10,000 |
| Acquisitions & other investing | −$50,495 | $200,000 | $6.3M | $4 | — | $250,000 | −$249,997 | −$250,000 | −$250,000 | $10,000 |
| Cash from investing activities | −$50,500 | $6.3M | $3.4M | −$10.1M | — | −$250,000 | −$250,000 | −$250,000 | −$250,000 | −$10,000 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | −$4.8M | — | — | — | — | — |
| Share repurchases & issuance (net) | −$10,000 | −$174,964 | −$270,952 | $0 | −$196,751 | $0 | — | — | $100,000 | $100,000 |
| Net borrowing (repayment) | — | — | — | $0 | −$1.6M | $693,920 | $1.0M | $1.4M | $581,450 | $127,500 |
| Shares issued | $7.2M | $1.6M | $0 | $15.5M | $15.2M | $0 | $0 | $0 | $0 | $0 |
| Other financing | $10,000 | $0 | $0 | $457 | $4.2M | $0 | −$41,699 | −$57,004 | $0 | $449,500 |
| Cash from financing activities | $7.2M | $1.5M | −$270,952 | $15.5M | $12.8M | $693,920 | $997,685 | $1.3M | $681,450 | $677,000 |
| Summary | ||||||||||
| Net change in cash | $1.3M | $2.5M | −$4.9M | −$2.4M | $10.6M | $9,364 | −$215,408 | $290,359 | −$208,171 | $221,768 |
| Cash at end of period | $7.2M | $5.9M | $3.5M | $8.3M | $10.7M | $98,012 | $88,648 | $304,056 | $13,697 | $221,868 |
| Free cash flow | −$5.9M | −$5.3M | −$8.1M | −$7.8M | −$2.2M | −$684,556 | −$1.2M | −$1.1M | −$889,621 | −$455,232 |
| Free cash flow margin | −97,607.4% | −48,193.6% | −90,309.8% | −8,800.2% | −2,525.0% | −416.1% | −733.0% | −845.9% | −18,533.8% | — |
| Capex / revenue | 0.1% | 1,818.2% | 1,111.1% | 0.0% | 0.0% | 152.0% | 0.0% | 0.0% | 0.0% | — |
| Operating cash flow / net income | — | — | — | — | −0.12 | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$1.5M | −$1.4M | −$1.9M | −$1.2M | −$1.2M | −$1.6M | −$1.9M | −$1.0M | −$1.6M | −$1.0M | −$1.7M | −$1.5M |
| Depreciation & amortization | $22,918 | $28,855 | $30,949 | $31,059 | $30,742 | $30,577 | $22,639 | $29,271 | $29,271 | $29,271 | $25,521 | $23,021 |
| Stock-based compensation | $0 | $0 | $0 | $0 | $0 | $3,485 | $9,162 | $9,162 | $9,162 | $9,162 | $9,162 | $9,162 |
| Change in working capital | $11,805 | $56,539 | −$79,245 | $52,557 | $43,814 | $12,500 | −$126,898 | $16,114 | $49,991 | $106,247 | −$217,005 | $94,614 |
| Other non-cash items | $2,922 | −$3,627 | −$1,584 | −$16,291 | $0 | $0 | −$365 | $0 | $0 | $0 | −$34,087 | $22,632 |
| Cash from operating activities | −$1.5M | −$1.3M | −$1.9M | −$1.2M | −$1.2M | −$1.6M | −$1.9M | −$985,588 | −$1.5M | −$896,864 | −$1.9M | −$1.3M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | −$125,000 | −$4 | $0 | −$3 | $0 | $0 | −$2 | −$4 | −$4 | −$100,000 | −$3 |
| Investments (net) | — | — | $0 | $0 | $0 | $0 | $0 | −$200,000 | $0 | $6.5M | $1.1M | $1.8M |
| Acquisitions & other investing | −$13,360 | −$36,640 | −$50,496 | — | — | — | — | $2 | — | $4 | $100,000 | $191,783 |
| Cash from investing activities | −$13,360 | −$161,640 | −$50,500 | — | — | — | — | −$200,000 | — | $6.5M | $1.1M | $2.0M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | $0 | $0 | −$10,000 | $10,000 | $0 | −$10,000 | $174,964 | −$25,450 | −$66,718 | −$82,796 | −$270,952 | −$191,780 |
| Shares issued | $0 | $0 | $7.2M | $0 | $0 | $0 | $1.6M | $0 | $0 | $0 | $0 | $0 |
| Other financing | $4.5M | $13,360 | −$3.3M | −$10,000 | $0 | $3.4M | −$174,964 | $0 | $100 | $0 | $0 | $0 |
| Cash from financing activities | $4.5M | $13,360 | $3.8M | $0 | $0 | $3.4M | $1.6M | −$25,450 | −$66,618 | −$82,796 | −$270,952 | −$191,780 |
| Summary | ||||||||||||
| Net change in cash | $3.0M | −$1.5M | $1.8M | −$1.2M | −$1.2M | $1.8M | −$320,036 | −$1.2M | −$1.5M | $5.5M | −$1.0M | $517,558 |
| Cash at end of period | $8.7M | $5.7M | $7.2M | $5.4M | $6.5M | $7.7M | $5.9M | $6.3M | $7.5M | $9.0M | $3.5M | $4.5M |
| Free cash flow | −$1.5M | −$1.3M | −$1.9M | −$1.2M | −$1.2M | −$1.6M | −$1.9M | −$985,590 | −$1.5M | −$896,860 | −$2.0M | −$1.3M |
| Free cash flow margin | — | — | −64,585.1% | — | — | −53,051.2% | −64,984.5% | — | −18,366.2% | −29,895.3% | −66,499.4% | −21,742.0% |
| Capex / revenue | — | — | 0.1% | — | — | 0.0% | 0.0% | — | 0.1% | 0.1% | 3,333.3% | 0.1% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CELZ cash generation
In fiscal 2025 (ended December 31, 2025), Creative Medical Technology generated -$5.9 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$5.9 million, −97,607.4% of revenue. It returned $0.0 million to shareholders through dividends ($0) and net share buybacks ($0.0 million). Cash and equivalents rose by $1.3 million over the year.
Related: CELZ income statement, CELZ balance sheet. See the CELZ stock overview for the latest quote and news.
CELZ cash flow FAQ
What is Creative Medical Technology's free cash flow?
Creative Medical Technology's free cash flow was -$5.9 million in fiscal 2025: -$5.9 million of operating cash flow minus $0.0 million of capital expenditures It was -$5.3 million a year earlier..
How much cash does Creative Medical Technology generate from operations?
Creative Medical Technology generated -$5.9 million of cash from operating activities in fiscal 2025.
How much does Creative Medical Technology spend on capital expenditures?
Creative Medical Technology spent $0.0 million on capital expenditures in fiscal 2025, 0.1% of revenue, compared with $0.2 million the year before.
How much stock does Creative Medical Technology buy back?
Creative Medical Technology spent $0.0 million on net share repurchases in fiscal 2025.